Certificate of added qualification for hepatology: vindication not vanity.

M. Fried

DOI: https://doi.org/10.1053/J.GASTRO.2005.02.052

IF: 29.4

2005-04-01

Gastroenterology

Abstract:

What problem does this paper attempt to address?

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

Jiajia Chen,Jianrong Huang,Yuemei Chen,Yinfeng Lu,Lanjuan Li

DOI: https://doi.org/10.5754/hge12025

2012-01-01

Abstract:BACKGROUND/AIMS:To focus on determining efficacy and safety of the combined artificial liver in treating severe hepatitis. METHODOLOGY:Ten patients with acute and chronic severe hepatitis were chosen for this study. A total of 19 cases were treated with a combination of selective plasma absorption and selective plasma exchange and 1 was treated with plasma perfusion absorption. Clinical symptoms and physical signs were observed. In addition, the changes in biochemical markers, coagulation function, and aminogram before and after selective plasma perfusion absorption treatment were compared. RESULTS:Ten patients were able to tolerate the treatment; 8 patients were cured or improved whereas 2 worsened. Statistically significant differences (p<0.05) were observed in the serum levels of total bilirubin, direct bilirubin, indirect bilirubin, alanine transaminase, aspartate transaminase, alkaline phosphatase, total bile acids, albumin and globulin before and after the selective perfusion absorption treatment. In contrast, no statistically significant differences (p>0.05) were observed in the serum concentrations of potassium, sodium, creatinine and urea nitrogen, as well as in prothrombin time, partial thromboplastin time and aminogram changes. CONCLUSIONS:The new perfusion absorber can markedly improve hepatic function without influencing the metabolism of micro-molecules and coagulation factors.
Clinical Evaluation of Treatment with Artificial Liver Support System in Chronic Fulminant Viral Hepatitis

黄建荣,李兰娟,陈月美,陈江华,朱琮,干梦九

DOI: https://doi.org/10.3760/j.issn:1003-0603.2001.04.004

2001-01-01

Abstract:Objective:To evaluate clinically the treatment with artificial liver support system (ALSS) in chronic fulminant viral hepatitis.Methods:Fiftyfive cases (162 episodes) were treated with ALSS,56 cases with convontional treatment as controls.Immunological and biochemical tests were performed before and after treatment with ALSS.Results:It showed that liver function parameters were markedly improved after treatment with ALSS,e.g.,serum globulin returned to normal,serum endotoxin decreased.There were no changes in levels of tumor necrosis factor(TNF),interleukin2(IL2) as well as interleukin2 receptor(IL2R),and blood electrolyte etc.after ALSS treatment.Complications of ALSS included rash,hypotention etc.,but most patients could tolerated well.Clinical curative rate in ALSS group was much higher than in the controls (61 8% vs.17 9%, P 0 01).Conclusions:Our results showed that ALSS treatment in chronic fulminant viral hepatitis could alleviate the organ damage and improve the clinical curetive rate.
Summary of Candidate Selection and Expanded Criteria for Liver Transplantation for Hepatocellular Carcinoma: A Review and Consensus Statement

K. Raj Prasad,Richard S. Young,Patrizia Burra,Shu-Sen Zheng,Vincenzo Mazzaferro,Duk Bog Moon,Richard B. Freeman

DOI: https://doi.org/10.1002/lt.22380

2011-01-01

Liver Transplantation

Abstract:K. Raj Prasad, Richard S. Young, Patrizia Burra, Shu-Sen Zheng, Vincenzo Mazzaferro, Duk Bog Moon, and Richard B. Freeman Department of Hepatobiliary Surgery and Transplantation, St. James’s University Hospital, Leeds, United Kingdom; Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, Italy; Division of Hepatobiliary and Pancreatic Surgery, Zhejiang University, Hangzhou, People’s Republic of China; Gastro-Intestinal Surgery and Liver Transplantation, National Cancer Institute, Milan, Italy; Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; and Division of Transplantation, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Guidelines for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Diseases

Min De Zeng,You Ming Li,Cheng Wei Chen,Lun Gen Lu,Jian Gao Fan,Bing Yuan Wang,Yi Min Mao

DOI: https://doi.org/10.1111/j.1751-2980.2008.00331.x

2008-01-01

Journal of Digestive Diseases

Abstract:Journal of Digestive DiseasesVolume 9, Issue 2 p. 108-112 Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases* Min De ZENG, Min De ZENG Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this authorJian Gao FAN, Jian Gao FAN Department of Gastroenterology, Shanghai First People's Hospital, Jiaotong University, Shanghai,Search for more papers by this authorLun Gen LU, Lun Gen LU Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this authorYou Ming LI, You Ming LI Department of Gastroenterology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,Search for more papers by this authorCheng Wei CHEN, Cheng Wei CHEN Clinical Center for Hepatology, No. 85 Army Hospital, Shanghai,Search for more papers by this authorBing Yuan WANG, Bing Yuan WANG Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, ChinaSearch for more papers by this authorYi Min MAO, Yi Min MAO Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this author Min De ZENG, Min De ZENG Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this authorJian Gao FAN, Jian Gao FAN Department of Gastroenterology, Shanghai First People's Hospital, Jiaotong University, Shanghai,Search for more papers by this authorLun Gen LU, Lun Gen LU Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this authorYou Ming LI, You Ming LI Department of Gastroenterology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,Search for more papers by this authorCheng Wei CHEN, Cheng Wei CHEN Clinical Center for Hepatology, No. 85 Army Hospital, Shanghai,Search for more papers by this authorBing Yuan WANG, Bing Yuan WANG Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, ChinaSearch for more papers by this authorYi Min MAO, Yi Min MAO Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,Search for more papers by this author First published: 16 April 2008 https://doi.org/10.1111/j.1751-2980.2008.00331.xCitations: 123 : Min De ZENG, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200001, China. Email: xhsyljd@yahoo.com.cn * The Chinese National Consensus Workshop on nonalcoholic fatty liver diseases was organized by Chinese Society of Hepatology, Chinese Medical Association. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume9, Issue2May 2008Pages 108-112 RelatedInformation
Letter to the editor: For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?

Xin Liu,Xiajie Wen,Fengmin Lu

DOI: https://doi.org/10.1016/j.jhep.2023.05.026

IF: 25.7

2023-06-11

Journal of Hepatology

Abstract:The authors of this study declare that they do not have any conflict of interest.

gastroenterology & hepatology
Comment on Saner et al. The Yin and the Yang of Hemostasis in End-Stage Liver Disease. J. Clin. Med. 2023, 12, 5759

Bruce D. Spiess,Wim P. M. Houdijk

DOI: https://doi.org/10.3390/jcm13061666

IF: 3.9

2024-03-15

Journal of Clinical Medicine

Abstract:We congratulate you on a quality review of the article on hemostasis in end-stage liver disease by Saner FH et al [...]

medicine, general & internal
Hepatologist Consultation in Low-Risk MASLD

Abigail Schubach,Rotonya M. Carr,Manal F. Abdelmalek

DOI: https://doi.org/10.1056/nejmclde2404875

IF: 158.5

2024-07-25

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 391, Issue 4, Page 373-375, July 25, 2024.

medicine, general & internal
Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance - Reply

Ang Cui,Raymond T. Chung,Nadia Alatrakchi

DOI: https://doi.org/10.1016/j.jhep.2024.08.001

IF: 25.7

2024-08-23

Journal of Hepatology

Abstract:The authors declare no conflict of interest related to this letter. Conflict of interests related to the original research was declared in the research publication.

gastroenterology & hepatology
Corrigendum to 'therapeutic HNF4A Mrna Attenuates Liver Fibrosis in a Preclinical Model' [J Hepatol (2021) 1420-1433].

Taihua Yang,Marion Poenisch,Rajendra Khanal,Qingluan Hu,Zhen Dai,Ruomeng Li,Guangqi Song,Qinggong Yuan,Qunyan Yao,Xizhong Shen,Richard Taubert,Bastian Engel,Elmar Jaeckel,Arndt Vogel,Christine S. Falk,Axel Schambach,Daniela Gerovska,Marcos J. Araúzo-Bravo,Florian W.R. Vondran,Tobias Cantz

DOI: https://doi.org/10.1016/j.jhep.2022.03.023

IF: 25.7

2022-01-01

Journal of Hepatology

Abstract:It has come to our attention that in the financial support statement, we erroneously acknowledged funding support from the PLUS3 programme of Boehringer Ingelheim. Funding support was actually received from the PLUS3 programme of the Boehringer Ingelheim foundation (an independent non-profit foundation). We apologise for any inconvenience caused.
Contemporary Issues in Liver Pathology

Prodromos Hytiroglou,Swan Thung

DOI: https://doi.org/10.1055/s-0031-1272830

2011-02-01

Seminars in Liver Disease

Abstract:The current issue of Seminars in Liver Disease is devoted to contemporary issues of hepatic pathology. In this era of rapid medical advances, pathology continues to play a very important role in the diagnosis and the assessment of severity of common and rare diseases, and to provide the interface between basic and clinical research. The biologic nature and clinical course of a variety of diseases are still elucidated by histopathologic study and clinicopathologic correlation, while the discovery of new immunohistochemical markers provides additional tools for research and diagnosis. Furthermore, understanding the pathologic basis of diseases is a prerequisite for a meaningful understanding of the corresponding molecular changes, clinical manifestations, and radiologic features, and for planning appropriate treatments. In this issue of Seminars, Morotti and collaborators from the Departments of Pathology and Pediatrics at The Mount Sinai Medical Center in New York City review the pathologic findings of progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3, which represent recently characterized conditions that are due to mutations in specific genes involved in bile acid formation and transport. Electron microscopy and recently developed immunohistochemical markers are useful in the diagnosis of these disorders. Fabris and Strazzabosco from the Department of Surgical and Gastroenterological Sciences of the University of Padova and from the Department of Internal Medicine of Yale University provide an in-depth review of the properties of the different cell types and mediators involved in the epithelial–mesenchymal interactions occurring in biliary diseases, and analyze the molecular mechanisms underlying this cross-talk as they relate to liver repair. Tsui and collaborators from the Departments of Pathology, Medicine and Geriatrics, and Radiology of Caritas Medical Centre in Hong Kong provide a fresh look at hepatolithiasis (also known as recurrent pyogenic cholangitis), a disease that is increasingly encountered outside of endemic areas, due to global migration. The authors discuss the radiologic and histologic features that are important in the diagnosis and differential diagnosis of this condition, and emphasize the importance of a multidisciplinary team approach for optimal patient outcome. Sempoux from the Department of Pathology of the Saint Luc University Clinics in Brussels and collaborators from the Departments of Surgery and Pathology at The Mount Sinai Medical Center review their extensive experience with intrahepatic peripheral cholangiocarcinoma, and provide evidence suggesting that cholangiocarcinomas with unusual (“nonclassical”) histologic features may often be related to chronic hepatitis C infection. Ward and Waxman from the Departments of Pathology and Medicine at The Mount Sinai Medical Center review the features of the fibrolamellar variant of hepatocellular carcinoma, a neoplasm with enigmatic etiology, emphasizing the genomic alterations, which appear to be fewer and less frequent than those of other hepatic malignancies, such as classic hepatocellular carcinoma, cholangiocarcinoma, and hepatoblastoma. Guido and Burra from the Pathology Unit and the Department of Gastroenterological and Surgical Sciences of the University of Padova review the pathologic and clinical features of de novo autoimmune hepatitis, a recently recognized disease occurring in liver allografts. Diagnosis of this serious disorder of obscure pathogenesis is often challenging, and requires careful clinicopathologic correlation. Germani and collaborators from the Departments of Surgery and Pathology of the Royal Free Hospital in London and from the Department of Pathology of the Aristotle University of Thessaloniki provide an update regarding the assessment of fibrosis in liver biopsy specimens. Although histologic examination remains the gold standard for staging chronic liver diseases, quantitative assessment of hepatic fibrosis by image analysis holds promise as a prognostic marker, and as a means to validate noninvasive markers of fibrosis. Last, but not least, Bioulac-Sage and collaborators from the Department of Pathology of the University of Bordeaux 2 and from Genomique Fonetionnelle des Tumeurs Solides in Paris revisit the pathology of benign hepatocellular nodules using novel immunohistochemical markers, derived from molecular studies. Their methodology allows the identification of clinically relevant subtypes of hepatocellular adenoma, as well as the differential diagnosis between unusual cases of focal nodular hyperplasia and hepatocellular adenoma. We are thankful to the authors for sharing their knowledge and experience with the readers of this issue of Seminars. We sincerely hope that this issue will be useful for pathologists, clinicians, and other scientists involved in the diagnosis, treatment, and research of hepatic diseases.

gastroenterology & hepatology
Letter: Prospective evaluation of patients with non‐cirrhotic portal hypertension—A single centre study. Authors' reply

Maria Mironova,Harish Gopalakrishna,Theo Heller

DOI: https://doi.org/10.1111/apt.18292

IF: 9.524

2024-09-29

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Mironova et al papers. To view these articles, visit https://doi.org/10.1111/apt.17987 and https://doi.org/10.1111/apt.18255

pharmacology & pharmacy,gastroenterology & hepatology
Correction: Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C

DOI: https://doi.org/10.1042/cs-2010-0387_cor

2024-06-20

Clinical Science

Abstract:Clin Sci (Lond). 2024 Jun 19;138(12):757-760. doi: 10.1042/CS-2010-0387_COR. NO

medicine, research & experimental
Correction to: Diagnosis and Treatment of Genetic HFE-Hemochromatosis: The Danish Aspect

Nils Thorm Milman,Frank Vinholt Schiodt,Anders Ellekar Junker,Karin Magnussen

DOI: https://doi.org/10.14740/gr1286c1

2023-04-29

Gastroenterology Research

Abstract:N/A Gastroenterol Res. 2023;16(2):125 doi: https://doi.org/10.14740/gr1286c1
Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States

Mondher Toumi,Jack Wallace,Chari Cohen,Chris Marshall,Helen Kitchen,Jake Macey,Hannah Pegram,Ashley F. Slagle,Robert G. Gish,Qin Ning,Hiroshi Yatsuhashi,Markus Cornberg,Maurizia Brunetto,Florian van Bömmel,Qing Xie,Dee Lee,Noriyuki Habuka,Urbano Sbarigia,Maria Beumont-Mauviel,Angelina Villasis Keever,Yasushi Takahashi,Yiwei Lu,Ao Liu,Qiaoqiao Chen,Tetsuro Ito,Olaf Radunz,Anna Puggina,Gudrun Hilgard,Eric K.H. Chan,Su Wang

DOI: https://doi.org/10.1186/s12889-023-17263-6

IF: 4.5

2024-02-28

BMC Public Health

Abstract:People with chronic hepatitis B (CHB) commonly experience social and self-stigma. This study sought to understand the impacts of CHB-related stigma and a functional cure on stigma.

public, environmental & occupational health
Elevated Plasma and Urine Levels of ADMA and 15(S)-8-iso-pgf2α in End-Stage Liver Disease

Dimitrios Tsikas,Iris Rode,Thomas Becker,Björn Nashan,Jürgen Klempnauer,Jürgen C. Frölich

DOI: https://doi.org/10.1002/hep.1840380440

IF: 17.298

2003-01-01

Hepatology

Abstract:HepatologyVolume 38, Issue 4 p. 1063-1064 CorrespondenceFree Access Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2α in end-stage liver disease Dimitrios Tsikas Ph.D., Dimitrios Tsikas Ph.D. Institute of Clinical Pharmacology, Hannover Medical School, Hannover, GermanySearch for more papers by this authorIris Rode Cd.M., Iris Rode Cd.M. Institute of Clinical Pharmacology, Hannover Medical School, Hannover, GermanySearch for more papers by this authorThomas Becker M.D., Thomas Becker M.D. Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, GermanySearch for more papers by this authorBjörn Nashan M.D., Ph.D., Björn Nashan M.D., Ph.D. Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, GermanySearch for more papers by this authorJürgen Klempnauer M.D., Jürgen Klempnauer M.D. Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, GermanySearch for more papers by this authorJürgen C. Frölich M.D., Jürgen C. Frölich M.D. Institute of Clinical Pharmacology, Hannover Medical School, Hannover, GermanySearch for more papers by this author Dimitrios Tsikas Ph.D., Dimitrios Tsikas Ph.D. Institute of Clinical Pharmacology, Hannover Medical School, Hannover, GermanySearch for more papers by this authorIris Rode Cd.M., Iris Rode Cd.M. Institute of Clinical Pharmacology, Hannover Medical School, Hannover, GermanySearch for more papers by this authorThomas Becker M.D., Thomas Becker M.D. Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, GermanySearch for more papers by this authorBjörn Nashan M.D., Ph.D., Björn Nashan M.D., Ph.D. Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, GermanySearch for more papers by this authorJürgen Klempnauer M.D., Jürgen Klempnauer M.D. Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, GermanySearch for more papers by this authorJürgen C. Frölich M.D., Jürgen C. Frölich M.D. Institute of Clinical Pharmacology, Hannover Medical School, Hannover, GermanySearch for more papers by this author First published: 07 March 2007 https://doi.org/10.1002/hep.1840380440Citations: 11AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume38, Issue4October 2003Pages 1063-1064 ReferencesRelatedInformation
Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply

Eunice X. X. Tan,Daniel Q. Huang,Mindie H. Nguyen

DOI: https://doi.org/10.1111/apt.18112

IF: 9.524

2024-06-14

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Eunice et al papers. To view these articles, visit https://doi.org/10.1111/apt.17914 and https://doi.org/10.1111/apt.17951

pharmacology & pharmacy,gastroenterology & hepatology
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice

Paul N Brennan,Oliver D Tavabie,Wenhao Li,Thomas Marjot,Lynsey Corless,Jonathan A Fallowfield,Helen Jarvis,Dina Mansour,Stuart McPherson,William Rosenberg,Karen Rockell,Jeremy Tomlinson,Andrew Yeoman,Emmanuel A Tsochatzis,John F Dillon,William Alazawi,Kushala W M Abeysekera

DOI: https://doi.org/10.1016/s2468-1253(23)00453-3

IF: 45.042

2024-02-01

The Lancet Gastroenterology & Hepatology

Abstract:The American, European, and Latin American liver societies have proposed a change in the nomenclature we use to describe alcohol-related liver disease and non-alcoholic fatty liver disease. Additionally, a term encompassing both is now advocated: steatotic liver disease, which includes metabolic dysfunction associated steatotic liver disease (MASLD) and MASLD with greater alcohol consumption (MetALD). These classifications offer increased relevance for clinicians, researchers, and patients alike. In this Viewpoint, we discuss the basis for this nomenclature shift and how it was developed. We also explore the challenges that will be faced in the adoption of such change. The proposed change seeks to banish stigma associated with phrasing such as alcoholic and fatty. However stigma, particularly related to the term fatty, is culturally nuanced, and reflects different entities depending on location. If such a change is internationally accepted, there will be wide-reaching effects on practitioners in primary care and metabolic medicine, and on patients. We discuss those effects and the opportunities the nomenclature change could offer, particularly for patients with alcohol and metabolic risk factors who represent a group previously ignored by clinical trials.

gastroenterology & hepatology
Correction to: Substitution of One Meat-Based Meal With Vegetarian and Vegan Alternatives Generates Lower Ammonia and Alters Metabolites in Cirrhosis: A Randomized Clinical Trial

Bryan D. Badal,Andrew Fagan,Victoria Tate,Travis Mousel,Mary Leslie Gallagher,Puneet Puri,Brian Davis,Jennifer Miller,Masoumeh Sikaroodi,Patrick Gillevet,Rolandas Gedgaudas,Juozas Kupcinskas,Leroy Thacker,Jasmohan S. Bajaj

DOI: https://doi.org/10.14309/ctg.0000000000000756

2024-08-20

Clinical and Translational Gastroenterology

Abstract:Correction to: Clin Transl Gastroenterol ;15(6):e1. doi: 10.14309/ctg.0000000000000707 Published online: June 2024

gastroenterology & hepatology
IMPACT OF A THERAPEUTIC EDUCATION PROGRAM OF MODIFICATION LIFE STYLE ON KNOWLEDGE, COMPLIANCE AND SATISFACTION OF PATIENTS TREATED FOR CHRONIC VIRAL HEPATITIS C

Khaled Hassan

DOI: https://doi.org/10.32553/ijmbs.v4i11.1533

2020-11-28

International Journal of Medical and Biomedical Studies

Abstract:Introduction: to help patients with chronic hepatitis C to modify their life style we need to therapeutic patient education (TPE) aiming to assess satisfaction and compliance of these patients with antiviral treatment. Objectives: to assess the impact after eight months of TPE program on the satisfaction and compliance of the patients treated for viral chronic hepatitis vs. Methods: through using questionnaire which distributed to 32 patients participated in at least one TPE consultation. 17 questions on knowledge and 20 patients was satisfied to answer the questionnaire Results:65% of the patients didn't not know answer to the questions before the first session of the program but after four TPE sessions, 76% of the patients give a precise answer about their knowledge and treatment sign scantly ( 0 . 01)), the viral load of 12 patients becomes negative during their treatment while 90.6% have good adherence to drug therapy. The patients were sati?ed with the TPE consultations. the program had positive impact on their everyday life Conclusions: TPE has a good an impact on the knowledge of the patients, it facilitate giving advice to the patients regarding the modification of their life style and medicinal treatment.
Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B—authors' reply

Anusha Vittal,Disha Sharma,Alvin Hu,Nehna A. Majeed,Sungyoung Auh,Marc G. Ghany

DOI: https://doi.org/10.1111/apt.16784

2022-02-09

Abstract:This article is linked to Vittal et al papers. To view these articles, visit https://doi.org/10.1111/apt.16659 and https://doi.org/10.1111/apt.16758

pharmacology & pharmacy,gastroenterology & hepatology

Certificate of added qualification for hepatology: vindication not vanity.

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

Clinical Evaluation of Treatment with Artificial Liver Support System in Chronic Fulminant Viral Hepatitis

Summary of Candidate Selection and Expanded Criteria for Liver Transplantation for Hepatocellular Carcinoma: A Review and Consensus Statement

Guidelines for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Diseases

Letter to the editor: For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?

Comment on Saner et al. The Yin and the Yang of Hemostasis in End-Stage Liver Disease. J. Clin. Med. 2023, 12, 5759

Hepatologist Consultation in Low-Risk MASLD

Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance - Reply

Corrigendum to 'therapeutic HNF4A Mrna Attenuates Liver Fibrosis in a Preclinical Model' [J Hepatol (2021) 1420-1433].

Contemporary Issues in Liver Pathology

Letter: Prospective evaluation of patients with non‐cirrhotic portal hypertension—A single centre study. Authors' reply

Correction: Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C

Correction to: Diagnosis and Treatment of Genetic HFE-Hemochromatosis: The Danish Aspect

Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States

Elevated Plasma and Urine Levels of ADMA and 15(S)-8-iso-pgf2α in End-Stage Liver Disease

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply

Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice

Correction to: Substitution of One Meat-Based Meal With Vegetarian and Vegan Alternatives Generates Lower Ammonia and Alters Metabolites in Cirrhosis: A Randomized Clinical Trial

IMPACT OF A THERAPEUTIC EDUCATION PROGRAM OF MODIFICATION LIFE STYLE ON KNOWLEDGE, COMPLIANCE AND SATISFACTION OF PATIENTS TREATED FOR CHRONIC VIRAL HEPATITIS C

Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B—authors' reply